This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OPKO Health (OPK) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.
Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Livongo Health (LVGO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Livongo Health's (LVGO) third-quarter results are likely to reflect growth in core Livongo for Diabetes solution.
Baxter (BAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) third-quarter performance is likely to reflect growth in its Acute Therapies business.
Stryker (SYK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) third-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at Diagnostics segment.
DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
Pacific Biosciences Unveils Sequel IIe for HiFi Sequencing
by Zacks Equity Research
Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology.
Are You Looking for a Top Momentum Pick? Why Pacific Biosciences of California (PACB) is a Great Choice
by Zacks Equity Research
Does Pacific Biosciences of California (PACB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pacific Biosciences (PACB) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Pacific Biosciences (PACB) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Pacific Biosciences' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Pacific Biosciences of California.
Pacific Biosciences (PACB) Up 82.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Catches Eye: Stock Jumps 6.6%
by Zacks Equity Research
Pacific Biosciences (PACB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Pacific Biosciences (PACB) Posts Lower-Than-Expected Q2 Loss
by Zacks Equity Research
Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 21.05% and 23.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences (PACB) Up 8.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allscripts Unit Inks Deal to Boost Veradigm AccelRx Platform
by Zacks Equity Research
This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.
Here's Why You Should Retain Masimo Stock (MASI) For Now
by Zacks Equity Research
Investor confidence remains high in Masimo (MASI) stock, thanks to solid prospects.
Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q2
by Zacks Equity Research
Varian (VAR) continued to gain from core Oncology Systems segment in Q2.
Luminex (LMNX) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Luminex's (LMNX) first-quarter earnings benefit from solid performance across Consumable Sales, Assay, Service and Other Revenues.
CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.
PRA Health (PRAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health's (PRAH) Clinical Research segment puts up a strong performance in Q1.